• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetes Metab Syndr. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis

tetano

Editor, Senior Moderator
Diabetes Metab Syndr. 2020 May 6;14(4):535-545. doi: 10.1016/j.dsx.2020.04.044. [Epub ahead of print]
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.


Kumar A[SUP]1[/SUP], Arora A[SUP]2[/SUP], Sharma P[SUP]3[/SUP], Anikhindi SA[SUP]4[/SUP], Bansal N[SUP]5[/SUP], Singla V[SUP]6[/SUP], Khare S[SUP]7[/SUP], Srivastava A[SUP]8[/SUP].

Author information




Abstract

BACKGROUND:

Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19.
METHODS:

We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods.
RESULTS:

We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity).
CONCLUSIONS:

Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done.
Copyright ? 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.



KEYWORDS:

2019-nCoV; COVID-19; Coronavirus; Diabetes mellitus; Novel coronavirus; SARS-CoV-2; nCoV-2019


PMID:32408118DOI:10.1016/j.dsx.2020.04.044
 
Back
Top Bottom